Although a combination of cisplatin and anti-PD-1 delayed tumor growth, the addition of DCP-IL-12/FLT3L to cisplatin improved the antitumor response, which was further ameliorated by PD-1 blockade (Fig. 5b). The gene discussed is FLT3LG; the disease is neoplasm.